Pharmaron is hosting an upcoming webinar titled What Makes a Good ADME Study? Key Considerations for Radiolabelled and 14C Studies on 22 September 2026 at 8 am PT / 11 am ET / 4 pm BST.

Pharmaron: Global Life Sciences Services Provider Stock Code: 300759.SZ/3759.HK Founded in 2004, Pharmaron is a premier life sciences service provider that offers a broad spectrum of research, development, and manufacturing service capabilities throughout the entire drug discovery, preclinical, and clinical development process across multiple therapeutic modalities, including small molecules, biologics, and CGT products. Pharmaron’s Comprehensive CRO & CDMO Services • Synthetic, Medicinal, and Analytical Chemistry Services • Biology Services (e.g., in vitro screening, structural biology, biomarkers) • DMPK Services (e.g., in vitro ADME, in vivo PK, PKPD, mass balance) • Pharmacology Services (e.g., in vivo pharmacology, animal disease models, immunotoxicity) • Drug Safety Assessment Services (e.g., toxicology, safety pharmacology, genetic toxicology) • Radiochemistry and Isotopically Labelled Metabolism Services (e.g., 14C/Carbon-14 radiosynthesis, 3H/tritium radiosynthesis, QWBA, mARG) • CMC Services (e.g., API manufacturing, process chemistry, formulation development) • Clinical Development Services (e.g., First-in-Human [FIH], ethnobridging, microdosing Phase 0, absolute bioavailability) Commitment to Excellence and Innovation With a proven track record of success, Pharmaron continually invests in its people, facilities, and technologies to meet evolving scientific and regulatory demands. The company prides itself on enabling scientific breakthroughs and supporting its partners in advancing human health. ____________________________________ Learn More: Explore Pharmaron’s services to discover how to accelerate your R&D programs. www.pharmaron.com. ________________________________________ Keywords: CRO, CDMO, synthetic chemistry, medicinal chemistry, biology, radiochemistry, toxicology, First-in-Human, API manufacturing, PKPD, 14C radiosynthesis, discovery biologics, clinical development, small molecules, biologics, cell and gene therapy (CGT) products